Mortality in DMARD and anti-TNF cohorts stratified by baseline RA-ILD
| DMARD | Anti-TNF | |||
|---|---|---|---|---|
| No baseline RA-ILD | Baseline RA-ILD | No baseline RA-ILD | Baseline RA-ILD | |
| Patients (n) | 3396 | 68 | 10350 | 299 |
| Total pyrs of follow-up | 8782 | 152 | 38423 | 1026 |
| Median (IQR) follow-up per person (years) | 2.6 (1.7–3.6) | 2.1 (1.3–3.1) | 3.9 (2.7–4.9) | 3.8 (2.0–4.7) |
| Deaths | ||||
| All-cause (n) | 181 | 14 | 635 | 70 |
| All-cause mortality/1000 pyrs | 21 (18 to 24) | 92 (50 to 155) | 17 (15 to 18) | 68 (53 to 86) |
| RA-ILD as cause, n (%) | 2 (1) | 1 (7) | 14 (2) | 15 (21) |
| RA-ILD on cert, n (%) | 4 (2) | 2 (14) | 25 (4) | 24 (34) |
| MRR (unadjusted (95% CI)) | Referent | 0.74 (0.42 to 1.33) | ||
| MRR (adjusted for age and gender (95% CI)) | Referent | 1.26 (0.69 to 2.31) | ||
| MRR (adjusted for age and gender and calendar year (95% CI)) | Referent | 1.14 (0.58 to 2.26) | ||
| MRR (fully adjusted* (95% CI)) | ||||
| Using patients with complete data sets | Referent | 0.80 (0.34 to 1.87) | ||
| Using imputed data | Referent | 0.81 (0.38 to 1.73) | ||
↵* Confounders included in multivariable model (adjusting point estimate by >10%) included age, gender, calendar year of entry, disease duration, HAQ, DAS28, COPD/asthma, baseline steroid use and baseline methotrexate use. (RhF, EARA, diabetes and smoking not identified as confounders.)
COPD, chronic obstructive pulmonary disease; DAS28, disease activity score; DMARD, disease-modifying antirheumatic drug; EARA, extra-articular manifestations of rheumatoid arthritis; HAQ, Health Assessment Questionnaire; MRR, mortality rate ratio; pyrs, person years; RA-ILD, rheumatoid arthritis-associated interstitial lung disease; RhF, rheumatoid factor; TNF, tumour necrosis factor.